Pancreatic Cancer Research

ResearcherUniversity of California, San FranciscoNo recent work listed

Wolfgang Michael Korn

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-0124-6841; OpenAlex author ID A5040325455. Sources: OpenAlex.

Their work

Papers
7 (first author 0, last author 4)
Trials
0
Grants
0
Labs led
1
Collaborators
40
Papers, trials and grants by year

2011: 1 paper · 2012: none · 2013: 1 paper · 2014: none · 2015: none · 2016: 1 paper · 2017: none · 2018: none · 2019: none · 2020: 1 paper · 2021: none · 2022: 2 papers · 2023: 1 paper

Papers 7

  1. Comparative Genomic Analysis of Pancreatic Acinar Cell Carcinoma (PACC) and Pancreatic Ductal Adenocarcinoma (PDAC) Unveils New Actionable Genomic Aberrations … Co-author DOI 10.1158/1078-0432.ccr-22-3724↗
  2. Molecular Characterization of KRAS Wild-type Tumors in Patients with Pancreatic Adenocarcinoma. Last author DOI 10.1158/1078-0432.ccr-21-3581↗
  3. Multi-omic Characterization of Pancreatic Ductal Adenocarcinoma Relates CXCR4 mRNA Expression Levels to Potential Clinical Targets. Co-author DOI 10.1158/1078-0432.ccr-22-0275↗
  4. Molecular characteristics of BRCA1/2 and PALB2 mutations in pancreatic ductal adenocarcinoma. Co-author DOI 10.1136/esmoopen-2020-000942↗
  5. A Multicenter, Open-Label Phase II Clinical Trial of Combined MEK plus EGFR Inhibition for Chemotherapy-Refractory Advanced Pancreatic Adenocarcinoma. Last author DOI 10.1158/1078-0432.ccr-15-0979↗
  6. Subtype-specific MEK-PI3 kinase feedback as a therapeutic target in pancreatic adenocarcinoma. Last author DOI 10.1158/1535-7163.mct-13-0104↗
  7. Autophagy suppression promotes apoptotic cell death in response to inhibition of the PI3K-mTOR pathway in pancreatic adenocarcinoma. Last author DOI 10.1007/s00109-011-0774-y↗

Closest collaborators

The 25 strongest of 40 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Emil Lou · 3 shared papers, 2022–2023 · strength 0.38
  2. Michael J. Hall · 3 shared papers, 2020–2022 · strength 0.31
  3. John Lindsay Marshall · 3 shared papers, 2020–2022 · strength 0.31
  4. Anthony Frank Shields · 3 shared papers, 2020–2022 · strength 0.31
  5. Wafik S. El‐Deiry · 2 shared papers, 2020–2022 · strength 0.20
  6. Philip A. Philip · 2 shared papers, 2020–2022 · strength 0.20
  7. Andreas Seeber · 2 shared papers, 2020–2022 · strength 0.19
  8. Florian Kocher · 2 shared papers, 2020–2022 · strength 0.19
  9. Alberto Puccini · 2 shared papers, 2020–2022 · strength 0.19
  10. Richard M. Goldberg · 2 shared papers, 2020–2022 · strength 0.19
  11. Heinz‐Josef Lenz · 2 shared papers, 2020–2022 · strength 0.19
  12. Rachna T. Shroff · 1 shared paper, 2023 · strength 0.16
  13. Kajsa E. Affolter · 1 shared paper, 2023 · strength 0.16
  14. Heloisa Prado Soares · 1 shared paper, 2023 · strength 0.16
  15. Courtney L. Scaife · 1 shared paper, 2023 · strength 0.16
  16. Chris Nevala-Plagemann · 1 shared paper, 2023 · strength 0.16
  17. Peter J. Hosein · 1 shared paper, 2023 · strength 0.16
  18. Ignacio Garrido‐Laguna · 1 shared paper, 2023 · strength 0.16
  19. Vaia Florou · 1 shared paper, 2023 · strength 0.16
  20. Davendra P. S. Sohal · 1 shared paper, 2022 · strength 0.12
  21. Ibrahim Hanna Azar · 1 shared paper, 2022 · strength 0.12
  22. Andrew Eugene Hendifar · 1 shared paper, 2022 · strength 0.12
  23. Moh'd M. Khushman · 1 shared paper, 2022 · strength 0.12
  24. David B. Spetzler · 1 shared paper, 2022 · strength 0.12
  25. A. Craig Lockhart · 1 shared paper, 2022 · strength 0.12

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.